Brian Woodard

Cooley advised WSO2, a leading provider of application development and identity and access management software to enterprise companies globally, on its agreement to be acquired by EQT’s BPEA Fund VIII (EQT Private Capital Asia).

Cooley advised Bonum Therapeutics, a biopharmaceutical company focused on creating highly active and less toxic medicines, on its $93 million Series A financing. Partner Sonya Erickson led the Cooley team advising Bonum Therapeutics.

Cooley advised Helion Energy, a clean energy company committed to creating a new era of plentiful, zero-carbon electricity from fusion, on its $500 million Series E financing round, which also includes an opportunity for an additional $1.7 billion tied to Helion reaching key performance milestones. Lawyers Sonya Erickson, Colleen Badgley, Ashley Brown, Justine Chiu and Jasjit Grewal led the Cooley team advising Helion.

Cooley advised Eliem Therapeutics on its $92 million initial public offering of 7,360,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Eliem Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol ELYM, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Partners Alan Hambelton, Sonya Erickson and Stephen Rosen led the Cooley team.

Cooley advised Accolade on its offering of $287.5 million principal amount of 0.50% convertible senior notes due 2026. Accolade, whose securities trade on the Nasdaq Global Select Market  under the symbol ACCD, is a provider of personalized, technology-enabled solutions that help people to understand, navigate and utilize the healthcare system and their workplace benefits.Partners Mischi a Marca, Alan Hambelton, John Robertson, and Jason Savich led the Cooley team.